Intralytix, Inc. and BioPhage Therapeutics Limited Partner to Develop Topical Bacteriophage Treatments of Human Wounds Infected With S. Aureus

Wednesday, April 5, 2017 Tropical Disease News
Email Print This Page Comment bookmark
Font : A-A+

BALTIMORE, April 4, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics

Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.

"Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected

wounds complicate healing, often necessitate repeated surgical interventions, and may lead to amputation of extremities or even death.  The problem is compounded by the increasing emergence of multi-antibiotic-resistant bacteria – such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) - that may colonize the wounds and make their successful treatment very difficult or even impossible to achieve," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist.  "The ultimate goal of our partnership with BioPhage is to develop and make commercially available a novel phage-based topical treatment approach for managing wounds infected with S. aureus, including wounds infected with multidrug-resistant or pan-resistant strains (i.e., strains resistant to all major classes of antibiotics)," Dr. Sulakvelidze added.

"We view this partnership as an important step in developing phage-based products for managing wounds infected with S. aureus," stated John Woloszyn, Intralytix's CEO.  "Working with BioPhage Therapeutics, we aim to rapidly bring our bacteriophage technology to the market, and to offer a natural, safe, and effective antimicrobial approach to millions of people suffering from infected, hard-to-heal wounds," Mr. Woloszyn added.

Intralytix, Inc. is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, and dietary supplements and probiotics.  The Company has the world's largest portfolio of FDA-approved phage preparations for food safety applications and is involved in the development of several additional products for human therapeutic, veterinary medicine, probiotic, and other applications.

BioPhage Therapeutics Limited is a British company with strong skills in the clinical development, registration, and marketing of therapeutic drug products.  "The partnership with Intralytix is ideal," stated Robert Jackson, Chairman of BioPhage.  "We can build upon Intralytix's strength in bacteriophage science by formulating their phage into a drug product that will be in clinical trials at leading UK teaching hospitals by the end of the year."

For more information, contact: 

At Intralytix: Mr. John Woloszyn (410-625-3813 or [email protected]) or Dr. Alexander Sulakvelidze (410-625-2533 or [email protected]).

At BioPhage: Mr. Robert Jackson (+44-7785-318254 or [email protected]) or Mr. Tim Butler (+44-7711-421944 or [email protected]).

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intralytix-inc-and-biophage-therapeutics-limited-partner-to-develop-topical-bacteriophage-treatments-of-human-wounds-infected-with-s-aureus-300434608.html

SOURCE Intralytix, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store